The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction
Open accessAbstract
IgA nephropathy frequently leads to progressive CKD. Although interest surrounds use of immunosuppressive agents added to standard therapy, several recent studies have questioned efficacy of these agents. Depleting antibody–producing B cells potentially offers a new therapy. In this open label, multicenter study conducted over 1-year follow-up, we randomized 34 adult patients with biopsy–proven IgA nephropathy and proteinuria >1 g/d, maintained on angiotensin–converting enzyme inhibitors or angiotensin receptor blockers with well controlled BP and eGFR<90 ml/min per 1.73 m 2, to receive standard therapy or rituximab with standard therapy. Primary outcome measures included change in proteinuria and change in eGFR. Median baseline serum creatinine level (range) was 1.4 (0.8–2.4) mg/dl, and proteinuria was 2.1 (0.6–5.3) g/d. Treatment with rituximab depleted B cells and was well tolerated. eGFR did not change in either group. Rituximab did not alter the level of proteinuria compared with that at baseline or in the control group; three patients in each group had ≥50% reduction in level of proteinuria. Serum levels of galactose-deficient IgA1 or antibodies against galactose-deficient IgA1 did not change. In this trial, rituximab therapy did not significantly improve renal function or proteinuria assessed over 1 year. Although rituximab effectively depleted B cells, it failed to reduce serum levels of galactose-deficient IgA1 and antigalactose–deficient IgA1 antibodies. Lack of efficacy of rituximab, at least at this stage and severity of IgA nephropathy, may reflect a failure of rituximab to reduce levels of specific antibodies assigned salient pathogenetic roles in IgA nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Stone, J. H., Merkel, P. A., Spiera, R., Seo, P., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., St. Clair, E. W., Turkiewicz, A., Tchao, N. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909905 · Cited by 2,762
Self-citationEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D. C., Coppo, R., Cook, H. T., Feehally, J., Roberts, I. S. D., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., et al. (2009) · Kidney International · doi:10.1038/ki.2009.243 · Cited by 1,235
Self-citationThe Pathophysiology of IgA Nephropathy
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A. B., Renfrow, M. B., Wyatt, R. J., Scolari, F., Mestecky, J., Gharavi, A. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050464 · Cited by 910
Self-citationIntensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Lai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
Self-citationNatural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
D’Amico, G. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8966 · Cited by 499
Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial
Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., Fogazzi, G. B., Altieri, P., Ponticelli, C., & Locatelli, F. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000103869.08096.4f · Cited by 484
Hoffman, W., Lakkis, F. G., & Chalasani, G. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09430915 · Cited by 482
Li, L.-S., & Liu, Z.-H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00837.x · Cited by 475
Suzuki, H., Fan, R., Zhang, Z., Brown, R., Hall, S., Julian, B. A., Chatham, W. W., Suzuki, Y., Wyatt, R. J., Moldoveanu, Z., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38468 · Cited by 450
Self-citationPatients with IgA nephropathy have increased serum galactose-deficient IgA1 levels
Moldoveanu, Z., Wyatt, R. J., Lee, J. Y., Tomana, M., Julian, B. A., Mestecky, J., Huang, W.-Q., Anreddy, S. R., Hall, S., Hastings, M. C., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002185 · Cited by 422
Self-citationBarratt, J., & Feehally, J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005020134 · Cited by 386
Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-Year Study
Fervenza, F. C., Abraham, R. S., Erickson, S. B., Irazabal, M. V., Eirin, A., Specks, U., Nachman, P. H., Bergstralh, E. J., Leung, N., Cosio, F. G., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05080610 · Cited by 299
Self-citationAberrant IgA1 Glycosylation Is Inherited in Familial and Sporadic IgA Nephropathy
Gharavi, A. G., Moldoveanu, Z., Wyatt, R. J., Barker, C. V., Woodford, S. Y., Lifton, R. P., Mestecky, J., Novak, J., & Julian, B. A. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007091052 · Cited by 284
Self-citationIgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1
Suzuki, H., Moldoveanu, Z., Hall, S., Brown, R., Vu, H. L., Novak, L., Julian, B. A., Tomana, M., Wyatt, R. J., Edberg, J. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33189 · Cited by 277
Self-citationAutoantibodies Targeting Galactose-Deficient IgA1 Associate with Progression of IgA Nephropathy
Berthoux, F., Suzuki, H., Thibaudin, L., Yanagawa, H., Maillard, N., Mariat, C., Tomino, Y., Julian, B. A., & Novak, J. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010053 · Cited by 272
Self-citationZhao, N., Hou, P., Lv, J., Moldoveanu, Z., Li, Y., Kiryluk, K., Gharavi, A. G., Novak, J., & Zhang, H. (2012) · Kidney International · doi:10.1038/ki.2012.197 · Cited by 248
Self-citationLv, J., Zhang, H., Chen, Y., Li, G., Jiang, L., Singh, A. K., & Wang, H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.029 · Cited by 238
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Tang, S. C. W., Tang, A. W. C., Wong, S. S. H., Leung, J. C. K., Ho, Y. W., & Lai, K. N. (2010) · Kidney International · doi:10.1038/ki.2009.499 · Cited by 192
Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis
Leiper, K., Martin, K., Ellis, A., Subramanian, S., Watson, A. J., Christmas, S. E., Howarth, D., Campbell, F., & Rhodes, J. M. (2011) · Gut · doi:10.1136/gut.2010.225482 · Cited by 178
Risk Stratification of Patients With IgA Nephropathy
Barbour, S. J., & Reich, H. N. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.02.326 · Cited by 174
Cytokines Alter IgA1 O-Glycosylation by Dysregulating C1GalT1 and ST6GalNAc-II Enzymes
Suzuki, H., Raska, M., Yamada, K., Moldoveanu, Z., Julian, B. A., Wyatt, R. J., Tomino, Y., Gharavi, A. G., & Novak, J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512277 · Cited by 170
Self-citationAn update on the pathogenesis and treatment of IgA nephropathy
Boyd, J. K., Cheung, C. K., Molyneux, K., Feehally, J., & Barratt, J. (2012) · Kidney International · doi:10.1038/ki.2011.501 · Cited by 164
Hogg, R. J., Bay, R. C., Jennette, J. C., Sibley, R. K., Kumar, S., Fervenza, F. C., Appel, G. B., Cattran, D., Fischer, D., Hurley, R. M., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.06.013 · Cited by 125
Self-citationBerthelot, L., Robert, T., Vuiblet, V., Tabary, T., Braconnier, A., Dramé, M., Toupance, O., Rieu, P., Monteiro, R. C., & Touré, F. (2015) · Kidney International · doi:10.1038/ki.2015.158 · Cited by 124
New Insights into the Pathogenesis of IgA Nephropathy
Novák, J., Rizk, D. V., Takahashi, K., Zhang, X., Bian, Q., Ueda, H., Ueda, Y., Reily, C., Lai, L., Hao, C., et al. (2015) · Kidney Diseases · doi:10.1159/000382134 · Cited by 92
Self-citationCD19+CD5+ B Cells in Primary IgA Nephropathy
He, Y., Ruijing, X., Xiang, J., Yanping, J., Chen, L., Li, L., Dingping, Y., Xinti, T., Jingyi, L., Zhiqing, T., et al. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121303 · Cited by 45
IgA1 Glycosylation Is Heritable in Healthy Twins
Lomax-Browne, H. J., Visconti, A., Pusey, C. D., Cook, H. T., Spector, T. D., Pickering, M. C., & Falchi, M. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016020184 · Cited by 34
Treatment of Progressive IgA Nephropathy: An Update
Wang, W., & Chen, N. (2013) · Contributions to nephrology · doi:10.1159/000348460 · Cited by 15
Cited by
Rodrigues, J. C., Haas, M., & Reich, H. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07420716 · Cited by 555
Floege, J., Barbour, S. J., Cattran, D. C., Hogan, J. J., Nachman, P. H., Tang, S. C. W., Wetzels, J. F. M., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.018 · Cited by 263
“Trials of rituximab and tacrolimus have yielded negative results.(94,95) Current trials address the spleen tyrosine kinase inhibitor fostamatinib, and the B-cell activating factor and a proliferation inducing ligand blocker atacicept (Figure 1).”
BackgroundSelf-citationSystematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
The pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
New strategies and perspectives on managing IgA nephropathy
Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01700-1 · Cited by 83
Metadata
- Authors
- Lafayette, R. A., Canetta, P. A., Rovin, B. H., Appel, G. B., Novak, J., Nath, K. A., Sethi, S., Tumlin, J. A., Mehta, K., Hogan, M., Erickson, S., Julian, B. A., Leung, N., Enders, F. T., Brown, R., Knoppova, B., Hall, S., & Fervenza, F. C.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-11-07
- Volume
- 28
- Issue
- 4
- Pages
- 1306-1313
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2557141247
- Cited by
- 300
- References
- 31
- FWCI
- 16.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.